Novel Biologics for the Treatment of Pediatric Severe Asthma

被引：1

作者：

Licari, Amelia ^{[1
,2
]}

Castagnoli, Riccardo ^{[2
]}

Tondina, Enrico ^{[2
]}

Testa, Giorgia ^{[1
]}

Parisi, Giuseppe Fabio ^{[3
]}

Marseglia, Alessia ^{[2
]}

Brambilla, Ilaria ^{[1
,2
]}

Marseglia, Gian Luigi ^{[1
,2
]}

机构：

[1] Fdn IRCCS Policlin San Matteo, SC Pediat, Pavia, Italy

[2] Univ Pavia, Dept Pediat, Pavia, Italy

[3] Univ Catania, Dept Clin & Expt Med, Catania, Italy

来源：

CURRENT RESPIRATORY MEDICINE REVIEWS | 2019年 / 15卷 / 03期

关键词：

Benralizumab; children; dupilumab; mepolizumab; omalizumab; reslizumab; severe asthma; SEVERE EOSINOPHILIC ASTHMA; SEVERE ALLERGIC-ASTHMA; ANTI-IGE; IMMUNOGLOBULIN-E; DOUBLE-BLIND; AIRWAY INFLAMMATION; MONOCLONAL-ANTIBODY; QGE031; LIGELIZUMAB; RANDOMIZED-TRIAL; SERUM IGE;

D O I：

10.2174/1573398X15666190521111816

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Estimated to represent less than 5% of all asthmatic patients, children with severe asthma experience troublesome persistent symptoms, life-threatening attacks and side effects by oral corticosteroid treatment, that significantly impact on the quality of life and on economic costs. An accurate understanding of the mechanisms of the disease has been crucial for the discovery and development of biological therapies, for which children with severe asthma are candidates. The aim of this review is to discuss the use of approved biologics for severe asthma, providing updated evidence of novel targeted therapies in the pediatric age range.

引用

页码：195 / 204

页数：10

共 50 条

[21] Promises and challenges of biologics for severe asthma
Tan, Ronnie
Liew, Mei Fong
Lim, Hui Fang
Leung, Bernard P.
Wong, W. S. Fred
BIOCHEMICAL PHARMACOLOGY, 2020, 179
[22] Global Access for Biologics in the Treatment of Severe Asthma: A Challenge to Personalized Medicine
Menzies-Gow, A.
Tran, T. N.
Hosseini, N.
Eleangovan, N.
Rowlands, M.
Bulathsinhala, L.
Hew, M.
Upham, J. W.
Heaney, L. G.
Ulrik, C.
Larenas-Linnemann, D.
Boven, J.
Fitzgerald, J. M.
Alacqua, M.
Wang, E.
Al-Ahmad, M.
Cosio, B. G.
Jackson, D. J.
Perez-de-Llano, L.
Porsbjerg, C.
Rasmussen, L. M.
Schmid, J.
Papaioannou, A.
Loukides, S.
Kallieri, M.
Lugogo, N.
Tan, A.
Chaudhry, I.
Carter, V.
Murray, R.
Price, D. B.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[23] The perceived waning of biologics in severe asthma
Kroes, J. A.
Van Hal, L. H. G.
Van Dijk, L.
Zielhuis, S. W.
Van Der Meer, A. N.
Van Roon, E. N.
Ten Brinke, A.
RESPIRATORY MEDICINE, 2023, 219
[24] Tailored Biologics Selection in Severe Asthma
Kim, Sang Hyuk
Kim, Youlim
TUBERCULOSIS AND RESPIRATORY DISEASES, 2024, 87 (01) : 12 - 21
[25] Adverse events in biologics for severe asthma
Dargentolle, G.
Georges, M.
Beltramo, G.
Poisson, C.
Bonniaud, P.
REVUE DES MALADIES RESPIRATOIRES, 2024, 41 (05) : 372 - 381
[26] Criteria for evaluation of response to biologics in severe asthma - the Biologics Asthma Response Score (BARS)
Milger, Katrin
Korn, Stephanie
Feder, Claudia
Fuge, Jan
Muehle, Andreas
Schuette, Wolfgang
Skowasch, Dirk
Timmermann, Hartmut
Suhling, Hendrik
PNEUMOLOGIE, 2023, 77 (04): : 220 - 232
[27] Criteria for evaluation of response to biologics in severe asthma - the Biologics Asthma Response Score (BARS)
Milger, Katrin
Korn, Stephanie
Feder, Claudia
Fuge, Jan
Muehle, Andreas
Schuette, Wolfgang
Skowasch, Dirk
Timmermann, Hartmut
Suhling, Hendrik
PNEUMOLOGIE, 2023,
[28] Biologics for the treatment of moderate-to-severe ulcerative colitis in pediatric patients
Albenberg, Lindsey G.
Mamula, Petar
Kelsen, Judith R.
PEDIATRIC HEALTH MEDICINE AND THERAPEUTICS, 2012, 3 : 51 - 58
[29] Current Biologics in Asthma Treatment
Imanirad, Donya
Tabatabaian, Farnaz
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 43 (05) : 627 - 634
[30] The potential of biologics for the treatment of asthma
Pelaia, Girolamo
Vatrella, Alessandro
Maselli, Rosario
NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (12) : 958 - 972

← 1 2 3 4 5 →